Arboretum Ventures

Arboretum Ventures LLC is a venture capital firm based in Ann Arbor, Michigan, founded in 2002. The firm specializes in seed-stage, early-stage, mid-stage investments, and growth capital, primarily focusing on the healthcare sector. Its investment areas include medical devices, diagnostics, healthcare information technology, therapeutics, technology-based healthcare services, and life science tools. Arboretum Ventures aims to invest between $5 million and $15 million in companies across the United States, with a particular emphasis on the Midwest and Michigan. The firm is recognized for its commitment to fostering innovation within the healthcare industry.

Cheryl Brown

Financial Analyst

Robert Cesaro

Associate

Jan Garfinkle

Founder and Managing Partner

Sarah Jameson

Senior Associate

James Kim

Associate

Marcy Marshall

CFO

Paul McCreadie

Partner and COO

Keegan McGuire

Associate

Tim Petersen

Founder and Managing Partner

Thomas Shehab

Managing Partner

Charity Tarn

Senior Associate

Nicole Walker

Managing Partner

104 past transactions

Shoulder Innovations

Series E in 2025
Shoulder Innovations, Inc. is a medical device company based in Holland, Michigan, specializing in orthopedic solutions for shoulder replacement surgery. Founded in 2009, the company has developed a Total Shoulder Replacement System that features innovative inset glenoid fixation technology, addressing the critical challenge of reliable fixation for glenoid implants. This technology not only enhances post-surgical implant stability, reducing the risk of revision surgeries, but also simplifies surgical instrumentation, which can lead to shorter operative times and lower costs. Shoulder Innovations markets its products through distribution partners across the United States, aiming to improve patient care and reduce overall healthcare costs.

Francis Medical

Series C in 2025
Francis Medical is a medical technology company focused on developing innovative therapeutic solutions for prostate, kidney, and bladder cancer. The company employs a novel water vapor technology that utilizes thermal energy from sterile water vapor to ablate cancerous tissue through a minimally invasive transurethral procedure. This approach aims to effectively treat endourological cancers while minimizing the life-altering side effects often associated with conventional treatments. By harnessing the energy stored in small amounts of water, Francis Medical seeks to enhance treatment efficacy and protect surrounding healthy structures, offering patients a potentially safer alternative in cancer care.

Orasis Pharmaceuticals

Series D in 2024
Orasis Pharmaceuticals Ltd is focused on developing innovative treatments for presbyopia, a common age-related vision condition. Founded in 2015 and based in Herzliya, Israel, the company has developed CSF-1, a corrective eye drop designed to improve near visual acuity through pupil modulation. This product aims to enhance the quality of life for individuals with presbyopia by alleviating the need for reading glasses. CSF-1 repurposes existing, well-studied molecules to ensure its effectiveness while prioritizing safety, comfort, and ease of use for patients. By providing a noninvasive treatment option, Orasis Pharmaceuticals offers a promising solution for those struggling with the symptoms of presbyopia.

RareCyte

Venture Round in 2024
RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.

AtaCor Medical

Series C in 2024
AtaCor Medical, Inc. is a medical device company based in San Clemente, California, focused on cardiac pacing and rhythm management. Founded in 2014, the company has developed the AtaCor EV Temporary Pacing System, an innovative implantable system that utilizes a parasternal approach to provide temporary pacing without the need for traditional leads or hardware attached to the heart. This system introduces a pacing lead into the extracardiac tissue located between the ribs and pericardium, allowing for quick and effective restoration of cardiac rhythm in patients. AtaCor Medical aims to enhance the delivery of temporary, interim, and permanent cardiac pacing solutions in critical situations.

ViaLase

Series C in 2024
ViaLase is a medical technology company based in Corona Del Mar, California, that specializes in developing an innovative image-guided femtosecond laser surgical system for treating open-angle glaucoma. Founded in 2019, the company utilizes micron-resolution optical coherence tomography (OCT) to guide its laser technology in creating precise, micron-sized drainage channels through the trabecular meshwork. This approach connects the anterior chamber to Schlemm's canal without the need for surgical incisions or penetration of the eye, thereby offering a non-invasive treatment option for glaucoma management. By enhancing the efficiency of glaucoma procedures, ViaLase aims to improve patient outcomes in this challenging area of ophthalmic care.

Flosonics Medical

Series C in 2024
Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

Reprieve Cardiovascular

Series A in 2024
Reprieve Cardiovascular, Inc. is a medical device company based in Milford, Massachusetts, founded in 2018. The company specializes in developing innovative fluid management technologies aimed at treating congestive heart failure, particularly for patients experiencing acute decompensated heart failure (ADHF). Its flagship product, Reprieve technology, offers a solution that allows clinicians to precisely control and manage a patient's fluid volume, which is crucial for improving cardiac care and facilitating the decongestion of ADHF patients. Reprieve Cardiovascular operates as a subsidiary of CardioRenal Systems, Inc.

Avation Medical

Series C in 2024
Avation Medical, Inc. is focused on developing a non-invasive closed-loop neuromodulation system designed for the at-home treatment of overactive bladder. Established in 2016 and based in Columbus, Ohio, the company is pioneering wearable nerve stimulation platforms that emphasize patient empowerment and personalized care. By re-imagining neuromodulation through innovative, proven technologies, Avation Medical aims to enhance the management of chronic conditions, offering solutions that prioritize the needs and experiences of patients.

Virtual Incision

Series C in 2023
Virtual Incision is focused on developing innovative surgical solutions, specifically through its miniaturized robotic support device designed for colon resection. The company's flagship product, the MIRA (Miniaturized In vivo Robotic Assistant) Platform, is a pioneering device that aims to streamline surgical procedures by allowing for quick setup in the operating room without the need for heavy equipment. This technology is intended to assist surgeons in improving clinical outcomes while also addressing healthcare costs. Virtual Incision's approach represents a significant advancement in robotic-assisted surgery, with plans for future applications beyond colon resection.

Convergent Dental

Venture Round in 2023
Convergent Dental, Inc. is a dental equipment and technology company based in Needham, Massachusetts, established in 2011. The company specializes in developing Solea, a computer-aided CO2 laser system designed for both hard and soft tissue dental procedures. This innovative system aims to enhance the patient experience during dental surgeries by providing a quieter and more precise cutting mechanism compared to traditional laser systems. Utilizing patented technologies and advanced computer controls, Solea enables dentists to perform procedures more efficiently while minimizing discomfort for patients.

Cardiac Dimensions

Series D in 2023
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

BrightSpec

Series C in 2022
BrightSpec is a company based in Charlottesville, Virginia, specializing in innovative laboratory services and technology for analytical chemistry. It is known for its Fourier transform molecular rotational resonance (FT-MRR) platform, developed from research at the University of Virginia. This technology enables comprehensive characterization of molecules, offering sensitivity to distinguish between stereoisomers and isotopes. BrightSpec's products are particularly valuable in industries such as manufacturing process control, quality control, environmental monitoring, and formulation research. The FT-MRR platform enhances the analysis of complex mixtures without the need for chromatography, thereby improving efficiency for chemical manufacturers. By leveraging quantum theory, BrightSpec aims to revolutionize the connection between artificial intelligence and sample analytics, providing immediate results to its customers.

Boomerang Medical

Series A in 2022
Boomerang Medical is a female-led bioelectronic medical technology company based in Mountain View, California, on the campus of El Camino Hospital. The firm focuses on advancing the treatment of autoimmune diseases through innovative bioelectric neuromodulation technology. This technology has received Breakthrough Device Designation from the FDA for its potential to treat conditions such as Crohn's disease and ulcerative colitis. Boomerang Medical aims to enhance patient outcomes by providing more effective treatment options for individuals suffering from these chronic illnesses.

Delphinus Medical Technologies

Series D in 2022
Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

Navv Systems

Series A in 2022
Navv Systems provides healthcare-focused indoor location technology with the NavvTrack platform. Integrated with Apple Maps, NavvTrack empowers hospitals with high-resolution indoor maps and tools to easily locate and manage staff, equipment, and resources. Developed at Henry Ford Innovations in Detroit, Michigan, NavvTrack is deployed in multiple U.S. hospitals, where it streamlines enterprise device management, helps coordinate team workflows and reduces operational costs.

Enumera Molecular

Series A in 2022
Enumera Molecular is a life science tools company based in Ann Arbor, Michigan, focused on developing a scalable biomolecule assessment platform that enhances clinical diagnostics. The platform aims to simplify and accelerate the process of clinical liquid biopsy tests, making them more affordable and accessible. By transforming complex molecular testing into a straightforward and actionable tool, Enumera Molecular supports physicians in improving patient care through rapid diagnostic capabilities.

Koya Medical

Series B in 2022
Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.

ViaLase

Series A in 2021
ViaLase is a medical technology company based in Corona Del Mar, California, that specializes in developing an innovative image-guided femtosecond laser surgical system for treating open-angle glaucoma. Founded in 2019, the company utilizes micron-resolution optical coherence tomography (OCT) to guide its laser technology in creating precise, micron-sized drainage channels through the trabecular meshwork. This approach connects the anterior chamber to Schlemm's canal without the need for surgical incisions or penetration of the eye, thereby offering a non-invasive treatment option for glaucoma management. By enhancing the efficiency of glaucoma procedures, ViaLase aims to improve patient outcomes in this challenging area of ophthalmic care.

Convergent Dental

Series C in 2021
Convergent Dental, Inc. is a dental equipment and technology company based in Needham, Massachusetts, established in 2011. The company specializes in developing Solea, a computer-aided CO2 laser system designed for both hard and soft tissue dental procedures. This innovative system aims to enhance the patient experience during dental surgeries by providing a quieter and more precise cutting mechanism compared to traditional laser systems. Utilizing patented technologies and advanced computer controls, Solea enables dentists to perform procedures more efficiently while minimizing discomfort for patients.

Boomerang Medical

Seed Round in 2021
Boomerang Medical is a female-led bioelectronic medical technology company based in Mountain View, California, on the campus of El Camino Hospital. The firm focuses on advancing the treatment of autoimmune diseases through innovative bioelectric neuromodulation technology. This technology has received Breakthrough Device Designation from the FDA for its potential to treat conditions such as Crohn's disease and ulcerative colitis. Boomerang Medical aims to enhance patient outcomes by providing more effective treatment options for individuals suffering from these chronic illnesses.

Akadeum

Series B in 2021
Akadeum Life Sciences, Inc. is a life sciences company based in Ann Arbor, Michigan, founded in 2014. The company specializes in manufacturing microbubble cell separation products designed to facilitate the removal of target cells from biological samples. Its product line includes T cell and B cell isolation kits for both human and mouse cells, as well as products for red blood cell depletion. Akadeum utilizes buoyancy-activated cell sorting technology, employing microscopic microbubbles that capture target cells and float them to the surface for efficient removal. This innovative approach enhances the efficiency of downstream testing and analysis for medical practitioners. The company's products are available for purchase online, and it maintains a strategic partnership with Agilent Technologies.

Francis Medical

Series B in 2021
Francis Medical is a medical technology company focused on developing innovative therapeutic solutions for prostate, kidney, and bladder cancer. The company employs a novel water vapor technology that utilizes thermal energy from sterile water vapor to ablate cancerous tissue through a minimally invasive transurethral procedure. This approach aims to effectively treat endourological cancers while minimizing the life-altering side effects often associated with conventional treatments. By harnessing the energy stored in small amounts of water, Francis Medical seeks to enhance treatment efficacy and protect surrounding healthy structures, offering patients a potentially safer alternative in cancer care.

Allay Therapeutics

Series C in 2021
Allay Therapeutics is focused on developing innovative pain management solutions aimed at improving post-surgical recovery for patients. The company utilizes a proprietary technology platform that integrates validated non-opioid analgesics with biopolymers to create dissolvable therapeutic products. These products are designed to deliver targeted pain relief at the surgical site over extended periods, significantly longer than conventional pain treatments. Allay's lead investigational product, ATX101, is currently undergoing evaluation in a Phase 2 clinical trial for total knee arthroplasty surgeries. With a team of experienced entrepreneurs, scientists, and clinicians based in the San Francisco Bay Area and Singapore, Allay Therapeutics is dedicated to transforming the approach to pain management and addressing the limitations associated with opioid use.

RareCyte

Series G in 2021
RareCyte, Inc. is a life sciences company based in Seattle, Washington, specializing in the development of innovative platforms for the analysis of liquid and tissue biopsies. Founded in 2009, the company focuses on the detection and characterization of rare cells, particularly circulating tumor cells (CTCs) and circulating endothelial cells (CECs), which are critical for advancing precision medicine in oncology and cardiovascular disease. RareCyte's AccuCyte system offers an open platform that allows for the unbiased discovery and isolation of these rare cells from whole blood. The company provides a comprehensive suite of products, including sample preparation systems, staining kits, automated microscopy instruments, and imaging systems, which are utilized in various applications such as liquid biopsies, single-cell retrieval, and multi-parameter tissue analysis. By equipping researchers and medical professionals with advanced tools, RareCyte aims to enhance clinical research and foster the development of targeted therapies.

Strata Oncology

Series C in 2021
Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Navv Systems

Seed Round in 2021
Navv Systems provides healthcare-focused indoor location technology with the NavvTrack platform. Integrated with Apple Maps, NavvTrack empowers hospitals with high-resolution indoor maps and tools to easily locate and manage staff, equipment, and resources. Developed at Henry Ford Innovations in Detroit, Michigan, NavvTrack is deployed in multiple U.S. hospitals, where it streamlines enterprise device management, helps coordinate team workflows and reduces operational costs.

Flosonics Medical

Venture Round in 2021
Flosonics Medical is a medical device company based in Sudbury, Canada, founded in 2017. It specializes in the development of non-invasive sensors aimed at enhancing the management of critically ill patients. The company's flagship product, the FloPatch, is a wearable sensor designed to monitor blood flow in patients' necks following clinical interventions. This innovative device addresses critical clinical needs for healthcare professionals, including physicians, nurses, and paramedics, working in various settings such as ambulances, emergency departments, operating rooms, and intensive care units. By integrating wearable ultrasound technology with connected devices, Flosonics Medical provides portable and user-friendly solutions that facilitate hands-free operation and improve patient care.

EQRx

Series B in 2021
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Koya Medical

Venture Round in 2020
Koya Medical, Inc., founded in 2018 and based in Oakland, California, specializes in developing innovative therapeutic devices aimed at treating cancer-related chronic lymphedema and various venous diseases. The company focuses on creating wearable technology that delivers active compression therapy, which is designed to enhance movement and mobility for patients. Koya Medical's approach offers a personalized alternative to traditional compression methods, utilizing a sensor-based closed-loop system to provide tailored compression patterns. This technology addresses the needs of patients suffering from conditions such as lymphedema, chronic edema, and chronic venous insufficiency, thereby improving their quality of care and overall treatment outcomes.

Jumpcode Genomics

Funding Round in 2020
Jumpcode Genomics, founded by Keith Brown in 2016 and based in Carlsbad, California, specializes in genome technology aimed at enhancing sequencing workflows. The company has developed CRISPR-mediated rRNA depletion kits, utilizing its proprietary CRISPRclean technology to selectively remove unwanted nucleic acid molecules from sequencing libraries. This innovative approach aims to improve detection sensitivity and performance while maintaining the integrity of non-targeted sequences. By integrating seamlessly with standard library preparation services, Jumpcode Genomics' solutions help researchers reduce bias, lower costs, and simplify their workflows, thereby enabling more effective applications of genomic information to address various global challenges.

Cardiac Dimensions

Series C in 2020
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

Health Scholars

Series B in 2020
Health Scholars, Inc. is a company that specializes in medical simulation training software aimed at enhancing clinical education for healthcare providers. Established in 2017 and based in Westminster, Colorado, the company offers a range of virtual reality (VR) training solutions, including pre-hospital and in-hospital Advanced Cardiovascular Life Support (ACLS) training for first responders and clinicians, respectively. Additionally, Health Scholars provides VR training focused on mitigating surgical fire risks in operating rooms. Their platform is designed to be user-friendly and scalable across healthcare systems, allowing for the effective management and delivery of interactive training content. This approach not only offers a cost-effective solution but also enriches the educational experience for medical professionals.

EQRx

Series A in 2020
EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on transforming the drug discovery and delivery process to address the rising costs of medicines. Founded in 2019, EQRx aims to provide a market-based solution by leveraging advances in science and technology while collaborating with various healthcare stakeholders. The company has over ten programs in its pipeline targeting oncology and immune-inflammatory conditions, which include clinical and preclinical stages, as well as drug engineering initiatives. Among its key programs are Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab. Through its innovative approach, EQRx seeks to develop high-quality, patent-protected medicines more efficiently and cost-effectively than traditional pharmaceutical methods.

Fifth Eye

Series A in 2019
Fifth Eye Inc. is a medical software company that specializes in developing real-time analytics systems for monitoring hemodynamic instability in patients. The company's innovative software continuously analyzes a patient's clinical data to provide early warnings of potential health issues, allowing healthcare professionals to intervene proactively. It delivers rapid assessments, with initial scoring in just five minutes, and offers continuous monitoring without the need for baseline data or integration with electronic health records. By utilizing advanced artificial intelligence and real-time ECG data, Fifth Eye's system enhances clinical decision-making, aiming to improve patient outcomes, prevent adverse events, and reduce hospital stays and costs. Founded in 2017 and based in Ann Arbor, Michigan, Fifth Eye was previously known as Trove Analytics, Inc., before rebranding in June 2018.

Lucina

Seed Round in 2019
Lucina Health, Inc. is a data-driven enterprise SaaS company that specializes in maternity analytics, primarily serving health plans, Medicaid providers, and public entities. The company's flagship offering, Firefly, aggregates and analyzes both individual patient and population data in real-time, allowing for the identification of women at risk of preterm birth, typically within the first trimester. This platform provides personalized health improvement resources tailored to each woman's needs, facilitating better health decisions for both mothers and care managers. Additionally, Firefly includes a mobile app that enhances communication between the platform and patients, empowering women to take control of their pregnancy journey. Founded in 2008 and based in Louisville, Kentucky, Lucina Health was formerly known as Cervilenz Inc. and became a subsidiary of Unified Women's Healthcare LLC in 2020.

Pear Therapeutics

Series C in 2019
Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

SonarMD

Series A in 2018
SonarMD, LLC, based in Elgin, Illinois, develops a subspecialty practice platform focused on care coordination for patients with chronic conditions, particularly those related to gut health. The company offers services designed to improve the management of complex chronic diseases that often require high-cost medications. By enhancing patient engagement and optimizing specialty pharmacy resources, SonarMD aims to keep patients healthier and reduce hospitalizations. Their approach integrates care management solutions that streamline the healthcare experience for both patients and clinical teams, ultimately fostering better health outcomes.

Francis Medical

Series A in 2018
Francis Medical is a medical technology company focused on developing innovative therapeutic solutions for prostate, kidney, and bladder cancer. The company employs a novel water vapor technology that utilizes thermal energy from sterile water vapor to ablate cancerous tissue through a minimally invasive transurethral procedure. This approach aims to effectively treat endourological cancers while minimizing the life-altering side effects often associated with conventional treatments. By harnessing the energy stored in small amounts of water, Francis Medical seeks to enhance treatment efficacy and protect surrounding healthy structures, offering patients a potentially safer alternative in cancer care.

Strata Oncology

Series B in 2018
Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

Cardiac Dimensions

Series B in 2018
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

BioIQ

Venture Round in 2018
BioIQ, founded in 2005 and based in Atlanta, Georgia, is a health improvement technology company focused on enhancing corporate health and wellness programs. It offers a unique health screening platform and an ecosystem of tools designed to provide quantifiable wellness insights. BioIQ's solutions include humanized analytics, omnichannel communications, and care navigation services for health plans, employers, and government entities. The company collaborates with major employers and health companies across the United States, having successfully launched over 3,000 health improvement programs.

Pear Therapeutics

Series B in 2018
Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

Swift Biosciences

Series D in 2017
Swift Biosciences Inc. is a biotechnology company based in Ann Arbor, Michigan, specializing in the development and commercialization of next-generation sequencing (NGS) library preparation kits for genomics and clinical research. The company offers a comprehensive range of products, including RNA library kits, amplicon panels, hybridization capture kits, and specialized kits for cancer gene profiling and COVID-19 testing. Swift Biosciences aims to streamline NGS sample preparation processes through innovative reagents and protocols, enhancing the usability of data obtained from sequencing instruments. Its offerings cater to various applications such as whole-genome sequencing, metagenomics, and the analysis of circulating tumor cells. The company operates through a network of distributors across the Asia Pacific, Europe, the Middle East, and South America, and was incorporated in 2009.

Aira

Series B in 2017
Aira is dedicated to enhancing accessibility for individuals who are blind or have low vision. The company offers remote visual interpretation services through an app that connects users with highly trained Visual Interpreters. By streaming live video from the user's smartphone camera, these interpreters assist with a variety of tasks, including navigation and face recognition, enabling users to engage more fully in daily activities. Additionally, Aira has developed a wearable assistive product that utilizes smart glasses and an augmented reality dashboard, allowing certified agents to see what the user sees in real-time. This combination of technology and human support empowers visually impaired individuals to navigate their environments with greater independence and confidence.

Ebb Therapeutics

Series B in 2017
Ebb Therapeutics, Inc. is a company specializing in the development of a regional cerebral thermal therapy (RCTT) device aimed at addressing insomnia and sleep disorders. It offers the Ebb Insomnia Therapy, which is a drug-free solution designed to help individuals improve their sleep quality. Founded in 2008 and originally known as Cereve, Inc., the company is headquartered in Pittsburgh, Pennsylvania. Ebb Therapeutics focuses on innovative therapeutic approaches to enhance sleep health without the reliance on pharmaceuticals.

ConcertoCare

Venture Round in 2016
ConcertoCare is dedicated to delivering primary and complex care to seniors and other adult patients with unmet health and social needs. The company employs a tech-enabled, value-based care model that features three distinct in-home care approaches, all supported by its proprietary population health and analytics platform. ConcertoCare's interdisciplinary teams, led by experienced professionals in home-based geriatric medicine, digital health, palliative care, and healthcare analytics, utilize clinical decision support tools to enhance patient care. This innovative model aims to lower overall healthcare costs while improving health outcomes for its patients.

nVision Medical

Series B in 2016
nVision Medical Corporation is a medical device company focused on addressing female health issues, specifically infertility caused by fallopian tube dysfunction and ovarian cancer detection. Founded in 2009 and based in Saratoga, California, nVision Medical develops innovative devices that allow clinicians to assess the health of previously inaccessible areas of the female reproductive tract. The company aims to fill significant gaps in women's health innovation by creating technologies that enhance diagnosis and treatment options. As of 2018, nVision Medical operates as a subsidiary of Boston Scientific Corporation, further leveraging resources to advance its mission in the healthcare sector.

SI-BONE

Venture Round in 2016
SI-BONE, Inc. is a medical device company based in Santa Clara, California, specializing in the development and commercialization of implantable devices for the surgical treatment of the sacropelvic anatomy. Founded in 2008, the company offers the iFuse implant system, a minimally invasive solution designed to fuse the sacroiliac joint to alleviate lower back pain caused by sacroiliac joint dysfunction. The iFuse implant utilizes a patented titanium fixation system and a cannulated delivery method, making the procedure quicker and simpler compared to traditional open fusion techniques. In addition to the iFuse, SI-BONE's product portfolio includes other patented implants and instruments, such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which are used in various applications, including adult spinal deformity, degeneration, and pelvic trauma.

Strata Oncology

Series A in 2016
Strata Oncology, Inc. is a precision oncology company focused on improving cancer care by increasing patient access to clinical trials and expediting drug approvals. The company operates a national precision oncology platform that connects patient screening to streamlined enrollment in mutation-matched clinical trials. Strata collaborates with major healthcare systems to facilitate the genomic sequencing of cancer patients' biopsies in high-throughput laboratories, providing oncologists with timely tumor profiles that inform treatment decisions. Its offerings include The Strata Trial, StrataNGS for targeted DNA and RNA sequencing, and StrataPOINT, which integrates electronic medical records with molecular data to ensure comprehensive testing and follow-up for eligible patients. Strata also manages a portfolio of pharmaceutical-sponsored trials tailored to specific biomarkers and operates the Strata Precision Oncology Network, a collaborative effort among cancer centers to advance precision medicine. Founded in 2015 and headquartered in Ann Arbor, Michigan, Strata was previously known as Strata Oncology Research, Inc. until its name change in May 2016.

ArborMetrix

Series B in 2016
ArborMetrix, Inc. is a data analytics and technology company focused on enhancing healthcare outcomes and advancing research through its innovative platform. Founded in 2011 and headquartered in Ann Arbor, Michigan, ArborMetrix offers a range of solutions for the healthcare industry, including data collection and integration, performance measurement, and analytics. Its products, such as EpisodeMetrix, provide critical insights into payer claims data, helping healthcare payers and at-risk providers manage costs and improve specialty care quality. The company also offers RegistryMetrix, which allows for the creation of specialized clinical registries, and SurgicalMetrix, which analyzes the performance of surgical groups by integrating clinical, financial, and operational data. ArborMetrix serves a diverse clientele that includes specialty societies, medical device manufacturers, pharmaceutical companies, and health systems, delivering actionable insights to optimize clinical outcomes and financial performance.

Pear Therapeutics

Series A in 2016
Pear Therapeutics, Inc. is a healthcare company specializing in the discovery, development, and delivery of software-based therapeutics aimed at treating behavioral health disorders, including addiction, schizophrenia, anxiety, depression, and chronic insomnia. Founded in 2013 and headquartered in Boston, with an additional office in San Francisco, Pear Therapeutics offers a range of digital therapies designed to enhance treatment outcomes. Notable products include reSET, a tool for substance abuse treatment used alongside traditional therapy; reSET-O, which addresses opioid use disorder; and Somryst, aimed at chronic insomnia. The company also provides PearConnect, a patient services center that connects users with advocates, clinicians, and insurance providers to facilitate support and resource access throughout treatment. By integrating digital interventions with pharmaceuticals, Pear Therapeutics aims to improve patient engagement, clinical outcomes, and cost-effectiveness in healthcare.

IntelliCyt

Venture Round in 2015
IntelliCyt Corporation specializes in the development of high-throughput cell- and bead-based screening solutions tailored for the life sciences sector, particularly in drug discovery, antibody development, and immunology. Founded in 2006 and based in Albuquerque, New Mexico, the company offers a comprehensive iQue Screener platform that integrates instrumentation, software, and reagents to facilitate high-content multiplex analysis of samples in liquid suspension. This platform is complemented by ForeCyt software for data visualization and analysis, as well as MultiCyt screening kits designed for use with iQue Screeners. IntelliCyt’s innovative technologies significantly enhance the efficiency and cost-effectiveness of detecting and measuring cells and beads, addressing critical needs in pharmaceutical and biotechnology laboratories globally. As a subsidiary of Sartorius AG, IntelliCyt continues to lead in providing solutions that meet the demands of modern life sciences research while ensuring rapid and relevant results in various applications, including phenotypic small molecule drug discovery and in vitro toxicology.

Delphinus Medical Technologies

Series C in 2015
Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

Cardiac Dimensions

Series A in 2015
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

My Health Direct

Venture Round in 2014
My Health Direct, Inc. is a health services solutions company that specializes in digital care coordination, focusing on scheduling and booking healthcare appointments. The company's primary product, MyHealthDirect, is a referral management and online appointment-scheduling platform designed to enhance decision support, workflow management, and actionable analytics for various healthcare organizations. It connects hospitals, care management organizations, and community health initiatives to facilitate access to healthcare services. Founded in 2006 and originally known as Global Health Direct, the company is headquartered in Nashville, Tennessee. As of August 2019, My Health Direct operates as a subsidiary of Experian Health, Inc.

Cardiac Dimensions

Series A in 2014
Cardiac Dimensions, Inc. is a medical device company focused on developing minimally invasive treatments for heart failure and associated cardiovascular conditions. The company is known for its Carillon Mitral Contour System, a permanent implant designed to treat functional mitral regurgitation through a non-surgical, catheter-based approach that reshapes the mitral valve and reduces regurgitation. Established in 2000, Cardiac Dimensions is headquartered in Kirkland, Washington, with additional operations in Sydney, Australia, and Offenbach, Germany.

RethinkFirst

Series C in 2014
RethinkFirst is a company dedicated to empowering individuals and organizations by providing comprehensive behavioral health tools and support. Founded in 2008, RethinkFirst initially focused on scalable autism treatment training and caregiver support for underserved populations. Over the years, it expanded its offerings to include a full suite of special needs and behavior management solutions for the K-12 education sector, as well as employer and provider solutions for the broader autism and developmental disability community. Recognizing the widespread need for behavioral health support, RethinkFirst evolved its mission to address challenges faced by individuals with various behavioral health issues, including anxiety, depression, and substance abuse. The company now serves over 2,000 customers worldwide, including clinicians, educators, and employers, by offering cloud-based software platforms and evidence-based protocols that create supportive communities and help individuals reach their fullest potential. RethinkFirst's commitment to transforming the behavioral health landscape is evident in its goal to remove barriers to access and empower individuals with the necessary tools for healthier, happier lives.

NeuMoDx Molecular

Series B in 2014
NeuMoDx Molecular, Inc. is a molecular diagnostics company based in Ann Arbor, Michigan, founded in 2012. It specializes in developing solutions for molecular diagnostic testing in hospital and clinical reference laboratories. The company’s platform provides in-vitro testing tools that enhance the efficiency and cost-effectiveness of laboratory operations. By improving the capabilities of laboratory professionals, NeuMoDx aims to increase the adoption of molecular diagnostic testing among medical providers, facilitating earlier and more accurate disease identification and treatment. In 2013, NeuMoDx changed its name from Molecular Systems Corporation and has since become a subsidiary of QIAGEN N.V.

Advance Medical

Series B in 2013
Advance Medical is a leading telemedicine provider that specializes in delivering expert medical opinions and concierge-level medical advice to patients worldwide. Established in 1999, the company operates offices across the U.S., Europe, Asia, and South America. Advance Medical uniquely focuses on connecting patients with board-certified physicians who provide personalized consultations via phone or video, ensuring comprehensive medical guidance for various health issues. The services offered facilitate accurate diagnoses, tailored treatment plans, and recommendations for top healthcare facilities, fostering strong relationships between patients and medical professionals.

Adavium

Private Equity Round in 2013
Adavium Medical is a medical equipment and diagnostics company based in São Paulo, Brazil, established in 2011. The company focuses on commercializing an innovative portfolio of medical devices and diagnostic products, representing leading international manufacturers. With a workforce of over 300 employees, Adavium Medical operates a fully-integrated commercial platform that adheres to high standards. It boasts the largest customer base in Brazil, serving more than 2,500 clients in both premium and long-tail segments of the medical equipment and diagnostics market. This extensive reach significantly surpasses that of typical distributors and multinational companies in the region, positioning Adavium Medical as a key player in a fragmented industry.

Delphinus Medical Technologies

Series B in 2013
Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

ArborMetrix

Series B in 2013
ArborMetrix, Inc. is a data analytics and technology company focused on enhancing healthcare outcomes and advancing research through its innovative platform. Founded in 2011 and headquartered in Ann Arbor, Michigan, ArborMetrix offers a range of solutions for the healthcare industry, including data collection and integration, performance measurement, and analytics. Its products, such as EpisodeMetrix, provide critical insights into payer claims data, helping healthcare payers and at-risk providers manage costs and improve specialty care quality. The company also offers RegistryMetrix, which allows for the creation of specialized clinical registries, and SurgicalMetrix, which analyzes the performance of surgical groups by integrating clinical, financial, and operational data. ArborMetrix serves a diverse clientele that includes specialty societies, medical device manufacturers, pharmaceutical companies, and health systems, delivering actionable insights to optimize clinical outcomes and financial performance.

Fidelis SeniorCare

Series A in 2013
Fidelis SeniorCare, Inc., a managed care company, develops and administers health plans for assisted living residents in Michigan, North Carolina, and Texas. The company offers Medicare advantage special needs plans to cover the health needs of seniors living in nursing homes and assisted living communities; and individuals who require specialized healthcare. Its plans cover on-site primary care team visits, part D prescription drugs, monitoring and managing prescribed medications, transportation to the hospital or physician’s office, and skilled nursing services during a covered Medicare stay; preventive care, screening, vision/dental/hearing, and podiatry services; and emergency room, ambulance, and urgent care services. The company was founded in 2004 and is based in Schaumburg, Illinois.

IntelliCyt

Venture Round in 2013
IntelliCyt Corporation specializes in the development of high-throughput cell- and bead-based screening solutions tailored for the life sciences sector, particularly in drug discovery, antibody development, and immunology. Founded in 2006 and based in Albuquerque, New Mexico, the company offers a comprehensive iQue Screener platform that integrates instrumentation, software, and reagents to facilitate high-content multiplex analysis of samples in liquid suspension. This platform is complemented by ForeCyt software for data visualization and analysis, as well as MultiCyt screening kits designed for use with iQue Screeners. IntelliCyt’s innovative technologies significantly enhance the efficiency and cost-effectiveness of detecting and measuring cells and beads, addressing critical needs in pharmaceutical and biotechnology laboratories globally. As a subsidiary of Sartorius AG, IntelliCyt continues to lead in providing solutions that meet the demands of modern life sciences research while ensuring rapid and relevant results in various applications, including phenotypic small molecule drug discovery and in vitro toxicology.

Esperion

Venture Round in 2013
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

BAROnova

Series C in 2013
BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

Tangent Medical Technologies

Series B in 2012
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Tangent Medical Technologies

Venture Round in 2012
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Sonitus Medical

Series D in 2012
Sonitus Medical Inc. is a privately held medical device company based in San Mateo, California, focused on delivering innovative hearing solutions for patients with hearing difficulties. The company is recognized as an emerging leader in bone conduction hearing devices, particularly through its flagship product, the SoundBite Hearing System. This system is notable for being the world's first non-invasive and removable hearing solution, which transmits sound through the teeth, leveraging the principle of bone conduction. The device is FDA cleared as a prosthetic option for treating single-sided deafness and conductive hearing loss. Sonitus Medical aims to expand its technology for future applications, including mixed hearing loss and tinnitus, along with potential consumer and covert communication uses. Founded in June 2006, the company collaborates with otologists, ENTs, and audiologists to enhance the auditory experience for patients.

Uptake Medical

Series C in 2012
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Cervilenz

Series A in 2012
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

Hicuity Health

Series D in 2011
Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.

Tangent Medical Technologies

Series A in 2011
Tangent Medical Technologies, a development stage medical device company, was founded in Ann Arbor in 2009 based on technology exclusively licensed from the University of Michigan's Medical Innovation Center. The Company's mission is to improve infusion therapy for patients and healthcare workers with its proprietary, intravenous catheters and associated products. Tangent is led by an experienced, successful management team and the original inventors of the technology. The Company expects to begin generating commercial revenues from its lead product, the NovaCath™ Closed IV Catheter System, in 2012.

Cervilenz

Venture Round in 2011
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

NxThera

Series B in 2011
NxThera, Inc. is a medical technology company based in Maple Grove, Minnesota, established in 2008 and currently a subsidiary of Boston Scientific Corporation. The company specializes in convective water vapor energy technology aimed at treating endourological conditions, particularly benign prostatic hyperplasia (BPH), which affects over 32 million men in the United States. NxThera's innovative platform employs a minimally invasive vapor therapy that converts sterile water into thermal energy delivered to prostate tissue, providing an effective treatment option for patients suffering from urologic conditions, including prostate and kidney cancer. This approach aims to enhance urinary flow and improve overall patient quality of life while minimizing side effects commonly associated with traditional treatments.

Wellfount

Series A in 2011
Wellfount is an institutional pharmacy that focuses on providing comprehensive pharmacy services to long-term care facilities, such as nursing homes. The company offers drug regimen reviews, medication packaging, distribution, and charting solutions to enhance patient care. Utilizing innovative technologies, Wellfount significantly streamlines the medication order process, reducing the number of steps involved from physician to patient. This includes just-in-time dispensing at the point of care and integrating nursing documentation into a unified patient record. Wellfount's remote dispensing system is designed to improve patient safety and meet quality standards in medication delivery, while also enabling skilled nursing providers to minimize waste and enhance efficiency. Through these efforts, Wellfount aims to improve the overall quality of care for patients, regardless of their payer source.

My Health Direct

Series B in 2011
My Health Direct, Inc. is a health services solutions company that specializes in digital care coordination, focusing on scheduling and booking healthcare appointments. The company's primary product, MyHealthDirect, is a referral management and online appointment-scheduling platform designed to enhance decision support, workflow management, and actionable analytics for various healthcare organizations. It connects hospitals, care management organizations, and community health initiatives to facilitate access to healthcare services. Founded in 2006 and originally known as Global Health Direct, the company is headquartered in Nashville, Tennessee. As of August 2019, My Health Direct operates as a subsidiary of Experian Health, Inc.

PathCentral

Series B in 2010
PathCentral, based in Irvine, California, offers a comprehensive web-based enterprise software platform tailored for community pathologists. Developed by a team of pathologists and industry experts, PathCentral's solution consolidates all facets of a pathology practice, including ordering, laboratory workflow management, specimen tracking, transcription, test send-outs, professional consultations, diagnosis, reporting, billing, and financial analysis. The platform is designed to enhance the efficiency and effectiveness of anatomic pathology operations, allowing users to manage their day-to-day activities seamlessly. Additionally, it features a cloud-based professional network that enables pathologists to engage in online consultations from any location globally.

Accuri Cytometers

Series E in 2010
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Delphinus Medical Technologies

Series A in 2010
Delphinus Medical Technologies, Inc. is a medical imaging company based in Plymouth, Michigan, with a satellite office in Sunnyvale, California. Founded in 2009, the company specializes in developing and commercializing SoftVue, an innovative ultrasound technology designed for comprehensive breast imaging. This circular array transducer system provides three-dimensional and tomographic imaging, allowing for the examination of women's breasts to detect both benign and malignant masses, assess breast cancer risks, diagnose breast diseases, and monitor treatment. Delphinus serves hospitals and imaging clinics across the United States and internationally, offering a non-invasive, radiation-free solution that enhances the early detection of breast cancer while prioritizing patient comfort.

Uptake Medical

Series B in 2010
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

CardioMEMS

Venture Round in 2010
CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

CardioMEMS

Series F in 2009
CardioMEMS is a medical device company focused on the development and commercialization of proprietary wireless sensing and communication technology aimed at enhancing the management of severe chronic cardiovascular diseases, including heart failure, hypertension, and aneurysms. The company's innovative platform features miniature wireless sensors that can be implanted using minimally invasive techniques. These sensors transmit vital data, such as cardiac output, blood pressure, and heart rate, which are essential for effective patient management. By providing continuous monitoring, CardioMEMS' technology aims to improve patient outcomes and facilitate timely medical interventions.

Accuri Cytometers

Series D in 2009
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Cervilenz

Series A in 2009
CerviLenz is a new, disposable device that measure vaginal cervical length during a speculum exam. Cervical length is a powerful predictor of preterm birth risk and influences patient management decisions. CerviLenz gives clinicians an immediate, reliable method for measuring the cervix at the point of care. CerviLenz is manufactured and distributed by Cervilenz Inc. headquartered in Chagrin Falls, Ohio.

BAROnova

Series B in 2008
BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

HandyLab

Series D in 2008
HandyLab is a medical technology company that develops and manufactures molecular diagnostic assays and automation platforms The company’s proprietary platform reduces the time, cost, and complexity of testing while improving the quality of results. Using patented real-time microfluidic PCR technology, its products are positioned to decentralize nucleic acid testing. HandyLab was founded in 2000 and is based in Ann Arbor, Michigan. It was acquired by Becton, Dickinson and Company in 2009.

Accuri Cytometers

Series C in 2008
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Hicuity Health

Series B in 2008
Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.

Esperion

Series A in 2008
Esperion discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Mirabilis Medical

Series A in 2007
Mirabilis Medical, Inc. is a medical device company based in Bothell, Washington, that specializes in the development and manufacture of ultrasound devices aimed at the non-invasive treatment of uterine fibroids, a common condition affecting women. Established in 2004, the company provides innovative solutions for gynecologists, utilizing high-resolution ultrasound imaging to accurately locate and treat fibroid tissue deep within the body without the need for incisions or punctures. This proprietary technology allows for effective ablation of pathological tissue while minimizing damage to surrounding areas, positioning Mirabilis Medical as a key player in the field of gynecological treatments.

KFx Medical

Series B in 2007
KFx Medical specializes in developing and manufacturing innovative soft tissue fixation implants tailored for orthopedic sports medicine. The company offers a range of products designed for tissue fixation, which can be directly placed into bones with or without sutures. These implants are applicable in various orthopedic surgical procedures, allowing surgeons to effectively reattach tissue in regions such as the shoulder, knee, foot, and ankle. KFx Medical collaborates closely with leading orthopedic surgeons to create advanced technologies and reliable surgical implants, ultimately aiming to improve surgical outcomes for patients.

Accuri Cytometers

Series B in 2007
Accuri Cytometers was founded to address a compelling need: life scientists love the rapid cell-by-cell analysis capability of flow cytometers, but too few have a flow cytometer in their lab. The barriers for most researchers include cost of the instrument, complexity of the software, effort required for maintenance, and the large amount of bench space required for the instrument. As a result, the company is looking to develop affordable and robust cytometers.

Inogen

Series D in 2007
Inogen is a medical technology company that specializes in the development and manufacturing of portable oxygen concentrators for patients with chronic respiratory conditions. Its flagship product, the Inogen One system, offers a lightweight and convenient alternative to traditional stationary oxygen concentrators and oxygen tanks. Inogen markets its products to home medical equipment providers and directly rents them to patients. The company also operates internationally, distributing its products through large gas companies and home oxygen providers. While it serves a global market, the majority of its revenue is generated in the United States. Inogen is committed to enhancing the freedom and independence of oxygen therapy patients through innovative products and superior service.

Uptake Medical

Series A in 2006
Uptake Medical specializes in developing innovative medical technologies aimed at treating lung diseases. The company's flagship product, InterVapor™, is an endoscopic lung volume reduction therapy designed specifically for individuals with severe emphysema. This unique approach leverages the body’s natural healing processes and does not introduce any foreign materials into the lungs. Clinical studies have shown that InterVapor™ can lead to significant improvements in patients' breathing function, exercise capacity, and overall quality of life.

Hicuity Health

Series A in 2006
Hicuity Health is a leading provider of high acuity telehealth services, delivering care to over 115 hospitals across 30 states on a continuous basis. The company focuses on acute care telemedicine, offering ICU programs and evidence-based protocols that utilize advanced telehealth technology. By connecting U.S. board-certified intensivists, nurses, and onsite clinicians with patients and their families, Hicuity Health enhances critical care delivery. The organization operates multiple dedicated tele-care delivery centers and emphasizes a proven implementation and client service approach, ultimately aiming to improve patient outcomes and support healthcare providers and institutions.

BAROnova

Series A in 2006
BAROnova, Inc. is a clinical-stage medical-device company established in 2006 and based in Goleta, California. The company specializes in creating non-surgical, non-pharmacologic devices aimed at inducing weight loss. Its primary product, the TransPyloric Shuttle, is designed to be inserted into the stomach through the mouth via a straightforward endoscopic procedure. This device works by helping patients feel fuller more quickly, maintain that feeling of fullness for a longer duration, and delay gastric emptying. Through these innovative approaches, BAROnova aims to assist individuals in managing their weight effectively.

KFx Medical

Series A in 2005
KFx Medical specializes in developing and manufacturing innovative soft tissue fixation implants tailored for orthopedic sports medicine. The company offers a range of products designed for tissue fixation, which can be directly placed into bones with or without sutures. These implants are applicable in various orthopedic surgical procedures, allowing surgeons to effectively reattach tissue in regions such as the shoulder, knee, foot, and ankle. KFx Medical collaborates closely with leading orthopedic surgeons to create advanced technologies and reliable surgical implants, ultimately aiming to improve surgical outcomes for patients.

HealthMedia

Venture Round in 2005
HealthMedia, founded in 1998 by Dr. Victor Strecher, specializes in scalable behavior change interventions aimed at health and wellness, disease management, and medication compliance. The company has developed innovative programs that replicate the benefits of health coaching sessions without the need for an actual coach. Its unique methodology and technology deliver effective outcomes similar to traditional health coaching while leveraging the scalability of web content. HealthMedia also creates specialized programs for pharmaceutical companies and medical device manufacturers, addressing a range of health issues, including drug and alcohol addiction, mental illness, and chronic conditions such as hypertension and heart disease.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.